Rifampicin-resistant Mycobacterium tuberculosis among tuberculosis-presumptive cases at University of Gondar Hospital, northwest Ethiopia

Figures & data

Table 1 Sociodemographic and clinical characteristics of the study participants

Variables		n (total 1,820)	Percentage
Sex	Male	1,078	59.2
	Female	742	40.8
Age-group, years	<10	56	3.1
	10–16	61	3.4
	17–23	252	13.8
	24–30	427	23.5
	31–37	246	13.5
	38–44	238	13.1
	45–51	223	12.3
	52–58	118	6.5
	>58	199	10.9
History of treatment	Previously treated	1,515	83.2
	New cases	305	16.8
HIV status	Negative	621	34.1
	Positive	315	17.3
	Unknown	884	48.6
Year of diagnosis	2013	225	12.4
	2014	858	47.1
	2015	737	40.5

Table 2 Mycobacterium tuberculosis (MTB) among the study participants based on sex, age, history of TB treatment, and HIV status

Variables	MTB-positive cases, n (%)	MTB-negative cases, n (%)	Total	P-value
Sex				0.55
Male	260 (24.1)	818 (75.9)	1078
Female	188 (25.3)	554 (74.7)	742
Total	448 (24.6)	1372 (75.4)	1820
Age-group, years				0.001
<10	5 (10.2)	44 (89.8)	49
10–16	14 (20.6)	54 (79.4)	68
17–23	65 (25.8)	187 (74.2)	252
24–30	127 (29.8)	300 (70.2)	427
31–37	77 (31.3)	169 (68.7)	246
38–44	47 (19.8)	191 (80.2)	238
45–51	51 (22.9)	172 (77.1)	223
52–58	19 (16.1)	99 (83.9)	118
>58	43 (21.6)	156 (78.4)	199
Total	448 (24.6)	1,372 (75.4)	1,820
TB-treatment history				0.78
Previously treated cases	371 (24.5)	1,144 (75.5)	1,515
New cases	77 (25.2)	228 (74.8)	305
Total	448 (24.6)	1,372 (75.4)	1,820
HIV status				0.26
Positive	75 (23.8)	240 (76.2)	315
Negative	167 (26.9)	454 (73.1)	621
Unknown	206 (23.3)	678 (76.7)	884
Total	448 (24.6)	1,372 (75.4)	1,820

Table 3 Rif-resistant MTB among confirmed TB patients based on sex, age, treatment history, and HIV status

Variables	MTB^+/Rif^−, n (%)	MTB^+/Rif^+, n (%)	Total TB positives, n (%)	P-value
Sex				0.32
Male	215 (82.7)	45 (17.3)	260 (58)
Female	162 (86.2)	26 (13.8)	188 (42)
Total	377 (84.2)	71 (15.8)	448 (100)
Age-group, years				0.06
<10	5 (100)	0	5 (1.1)
10–16	13 (92.9)	1 (7.1)	14 (3.1)
17–23	49 (75.4)	16 (24.6)	65 (14.5)
24–30	103 (81.1)	24 (19.9)	127 (28.3)
31–37	67 (87)	10 (13)	77 (17.2)
38–44	45 (95.7)	2 (4.3)	47 (10.5)
45–51	46 (90.2)	5 (9.8)	51 (11.4)
52–58	14 (73.7)	5 (26.3)	19 (4.2)
>58	35 (81.4)	8 (18.6)	43 (10)
Total	377 (84.2)	71 (15.8)	448 (100)
TB-treatment history				0.54
Previously treated cases	310 (83.6)	61 (16.4)	371 (82.8)
New cases	67 (87)	10 (13)	77 (17.2)
Total	377 (84.2)	71 (15.8)	448 (100)
HIV status				0.33
Positive	61 (81.3)	14 (18.7)	75 (16.7)
Negative	146 (87.4)	21 (12.6)	167 (37.3)
Unknown	170 (82.5)	36 (17.5)	206 (46)
Total	377 (84.2)	71 (15.8)	448 (100)

Notes: MTB⁺/RIF⁻, MTB-positive, but not Rif-resistant. MTB⁺/RIF⁺: MTB-positive and Rif-resistant.

Abbreviations: MTB, Mycobacterium tuberculosis; Rif, rifampicin.

Figure 1 Rif-resistant MTB based on year of diagnosis.

Notes: MTB⁺/RIF⁻, MTB-positive, but not Rif-resistant. MTB⁺/RIF⁺: MTB-positive and Rif-resistant.

Abbreviations: MTB, Mycobacterium tuberculosis; Rif, rifampicin.